CN101121706B - 一种香豆素衍生物及其制备方法和用途 - Google Patents
一种香豆素衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN101121706B CN101121706B CN2007101318030A CN200710131803A CN101121706B CN 101121706 B CN101121706 B CN 101121706B CN 2007101318030 A CN2007101318030 A CN 2007101318030A CN 200710131803 A CN200710131803 A CN 200710131803A CN 101121706 B CN101121706 B CN 101121706B
- Authority
- CN
- China
- Prior art keywords
- compound
- methoxyl group
- preparation
- vinyl
- tonka bean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物编号 | R1 | R2 | R3 | R4 | R5 |
1 | H | H | H | H | H |
2 | H | H | CH<sub>3</sub> | H | H |
3 | CH<sub>3</sub> | H | H | H | H |
4 | H | CH<sub>3</sub> | CH<sub>3</sub> | H | H |
5 | H | -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- | H | H | |
6 | H | -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- | H | H | |
7 | H | H | OCH<sub>3</sub> | H | H |
8 | H | H | OH | H | H |
9 | H | OCH<sub>3</sub> | OCH<sub>3</sub> | H | H |
10 | H | OH | OH | H | H |
11 | H | H | OCH<sub>3</sub> | OCH<sub>3</sub> | OCH<sub>3</sub> |
12 | H | H | OH | OH | OH |
13 | H | -OCH<sub>2</sub>O- | H | H | |
14 | H | -OC(CH<sub>3</sub>)<sub>2</sub>O- | H | H |
13 | H | -OCH<sub>2</sub>O- | H | H | |
15 | H | H | NH<sub>2</sub> | H | H |
16 | H | H | NHCH<sub>3</sub> | H | H |
17 | H | H | NHCH<sub>2</sub>CH<sub>3</sub> | H | H |
18 | H | H | N(CH<sub>3</sub>)<sub>2</sub> | H | H |
19 | OCH<sub>3</sub> | H | H | NH<sub>2</sub> | H |
20 | OCH<sub>3</sub> | H | H | NHCH<sub>3</sub> | H |
21 | OCH<sub>3</sub> | H | H | NHCH<sub>2</sub>CH<sub>3</sub> | H |
22 | OH | H | H | NH<sub>2</sub> | H |
23 | OH | H | H | NHCH<sub>3</sub> | H |
24 | OH | H | H | NHCH<sub>2</sub>CH<sub>3</sub> | H |
25 | H | H | OPO<sub>3</sub>H | H | H |
26 | H | H | OPO<sub>3</sub>Na | H | H |
化合物编号 | 抑制率(%) | IC50μg/mL | |||||||
1.06μg/mL | 3.13μg/mL | 6.25μg/mL | 12.50μg/mL | 25.00μg/mL | 50.00μg/mL | 100.00μg/mL | 200.00μg/mL | ||
CA4 | 0 | 0 | 1.2 | 12.9 | 33.7 | 55.5 | 69.1 | 86.2 | 56.30 |
1 | 0 | 2.3 | 21.8 | 43.3 | 60.7 | 78.1 | 91.8 | 100.0 | 20.00 |
2 | 0 | 0 | 6.6 | 27.7 | 45.9 | 61.7 | 81.2 | 100.0 | 30.03 |
3 | 0 | 0 | 6.1 | 23.4 | 48.9 | 63.8 | 79.5 | 97.1 | 39.15 |
4 | 0 | 0 | 5.8 | 26.9 | 46.0 | 59.1 | 78.6 | 92.3 | 43.82 |
5 | 0 | 1.1 | 13.1 | 36.6 | 51.9 | 70.3 | 92.6 | 100.0 | 22.24 |
6 | 0 | 0 | 3.2 | 21.2 | 39.1 | 55.3 | 78.9 | 96.1 | 43.52 |
7 | 0 | 3.7 | 18.9 | 29.8 | 43.6 | 62.1 | 89.4 | 100.0 | 22.35 |
8 | 0 | 3.1 | 16.3 | 31.1 | 44.7 | 59.9 | 87.1 | 100.0 | 23.02 |
9 | 0 | 8.1 | 23.3 | 39.0 | 55.9 | 77.8 | 93.9 | 100.0 | 18.80 |
10 | 2.9 | 25.7 | 44.0 | 68.9 | 85.3 | 98.9 | 100.0 | 100.0 | 6.46 |
11 | 0 | 8.3 | 29.5 | 51.1 | 72.4 | 87.7 | 98.6 | 100.0 | 15.56 |
化合物编号 | 抑制率(%) | IC50μg/mL | |||||||
12 | 0 | 7.9 | 33.5 | 49.7 | 75.1 | 90.0 | 100.0 | 100.0 | 13.64 |
13 | 0 | 2.4 | 19.8 | 31.0 | 66.9 | 81.4 | 97.9 | 100.0 | 18.66 |
14 | 0 | 9.9 | 35.1 | 51.0 | 73.5 | 90.1 | 100.0 | 100.0 | 13.44 |
15 | 0 | 1.8 | 16.8 | 27.6 | 60.3 | 84.3 | 96.9 | 100.0 | 19.68 |
16 | 0 | 8.7 | 29.6 | 48.9 | 71.3 | 90.1 | 100.0 | 100.0 | 13.82 |
17 | 0 | 6.6 | 25.7 | 45.9 | 68.2 | 84.1 | 100.0 | 100.0 | 14.64 |
18 | 0 | 2.9 | 17.2 | 29.0 | 61.9 | 81.1 | 98.9 | 100.0 | 18.34 |
19 | 0 | 1.2 | 14.9 | 37.1 | 49.9 | 73.3 | 91.2 | 100.0 | 22.15 |
20 | 1.8 | 19.8 | 40.2 | 58.6 | 79.1 | 98.2 | 100.0 | 100.0 | 7.63 |
21 | 0 | 5.5 | 23.1 | 41.4 | 61.1 | 88.2 | 100.0 | 100.0 | 14.98 |
22 | 0 | 7.3 | 29.2 | 41.3 | 65.8 | 93.1 | 100.0 | 100.0 | 14.08 |
23 | 0 | 5.9 | 22.3 | 36.7 | 59.1 | 82.1 | 100.0 | 100.0 | 15.47 |
化合物编号 | 抑制率(%) | IC50μg/mL | |||||||
24 | 0 | 2.1 | 15.9 | 32.7 | 55.3 | 69.2 | 85.2 | 100.0 | 22.52 |
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101318030A CN101121706B (zh) | 2007-09-18 | 2007-09-18 | 一种香豆素衍生物及其制备方法和用途 |
PCT/CN2008/070118 WO2009036656A1 (fr) | 2007-09-18 | 2008-01-16 | Dérivés de coumarine, leurs procédés de préparation et leurs utilisations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101318030A CN101121706B (zh) | 2007-09-18 | 2007-09-18 | 一种香豆素衍生物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101121706A CN101121706A (zh) | 2008-02-13 |
CN101121706B true CN101121706B (zh) | 2010-11-24 |
Family
ID=39084227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101318030A Expired - Fee Related CN101121706B (zh) | 2007-09-18 | 2007-09-18 | 一种香豆素衍生物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101121706B (zh) |
WO (1) | WO2009036656A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103408530B (zh) * | 2013-08-26 | 2015-05-27 | 中国人民解放军第三军医大学 | 具有生物活性的香豆素骨架多环化合物及制备方法和用途 |
WO2018236138A1 (ko) * | 2017-06-20 | 2018-12-27 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
CN109985036A (zh) * | 2018-06-13 | 2019-07-09 | 上海交通大学医学院附属第九人民医院 | 蛇床子素的新用途及其应用 |
CN112062743B (zh) * | 2020-08-19 | 2023-01-10 | 浙江工业大学 | 一种白藜芦醇衍生物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1075632A (zh) * | 1991-11-09 | 1993-09-01 | 沙佩尔·布吕墨股份公司 | 烷氧基化苯基和香豆素衍生物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9920908D0 (en) * | 1999-09-03 | 1999-11-10 | Indena Spa | Chalcone coumarins |
-
2007
- 2007-09-18 CN CN2007101318030A patent/CN101121706B/zh not_active Expired - Fee Related
-
2008
- 2008-01-16 WO PCT/CN2008/070118 patent/WO2009036656A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1075632A (zh) * | 1991-11-09 | 1993-09-01 | 沙佩尔·布吕墨股份公司 | 烷氧基化苯基和香豆素衍生物及其应用 |
Non-Patent Citations (3)
Title |
---|
Jin-Na Cai,et al.Coumarins from the Fruits of Cnidium monnieri.J. Nat. Prod63 4.2000,63(4),485-488. |
Jin-Na Cai,et al.Coumarins from the Fruits of Cnidium monnieri.J. Nat. Prod63 4.2000,63(4),485-488. * |
JP特开平7-53554A 1995.02.28 |
Also Published As
Publication number | Publication date |
---|---|
CN101121706A (zh) | 2008-02-13 |
WO2009036656A1 (fr) | 2009-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105175410B (zh) | 三嗪类化合物及其制备方法和抗肿瘤应用 | |
CN104497014B (zh) | 一种手性氟喹诺酮C-3稠杂环α,β-不饱和酮衍生物及其制备方法和应用 | |
CN101121706B (zh) | 一种香豆素衍生物及其制备方法和用途 | |
CN109438365B (zh) | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 | |
CN105732468B (zh) | 一种n’-(2-(1h-吲哚-3-基)乙酰基)芳酰肼类化合物及其制备方法和用途 | |
CN104860993A (zh) | 一种黄酮化合物前药及其用途 | |
CN102617536A (zh) | 异黄酮类化合物,其制备方法及其在制备抗病毒或抗肿瘤药物中的应用 | |
CN104387389A (zh) | 1,2,3-三唑-黄酮类化合物-苦参碱三元轭联物和用途 | |
CN104072493A (zh) | 一类含2-巯基苯并噻唑和三唑杂环的萘酰亚胺化合物,其制备方法及其应用 | |
CN106316946B (zh) | 一种环丙沙星的α,β-不饱和酮衍生物及其制备方法和应用 | |
CN103649068A (zh) | 一种他汀类药物中间体和其制备方法 | |
CN109912571A (zh) | 具有生物活性的新型苯并喹啉取代三氮唑类化合物及其合成方法和应用 | |
CN108689982A (zh) | 一种具有α,β-不饱和酮结构片段的香豆素衍生物及其制备方法和用途 | |
CN103086859A (zh) | 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用 | |
CN110922415A (zh) | 一种新型抗肿瘤活性化合物的合成与应用 | |
CN101186606B (zh) | 蛇葡萄素衍生物、其合成方法及其在制备抗肿瘤药物中的应用 | |
CN105949161A (zh) | 一种3-芳巯基黄酮化合物的制备方法 | |
CN102532082A (zh) | 2,2-二甲基苯并吡喃类化合物及其制备方法和应用 | |
CN104844590A (zh) | 一种n-甲基环丙沙星(绕丹宁不饱和酮)酰胺类衍生物及其制备方法和应用 | |
CN107266356A (zh) | 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用 | |
CN102212032B (zh) | 一种5-羟基喹诺酮类衍生物及其制备方法和用途 | |
CN106038560B (zh) | 一类含硫穿心莲内酯衍生物在制备治疗前列腺癌药物中的应用 | |
CN104098524B (zh) | 1-间甲氧基苯甲酰基-3-苯基-1,4-二氢-1,2,4,5-四嗪及制备和应用 | |
CN104003966A (zh) | 5,7,2’,4’-四羟基-3-烃基黄酮类似物及其制备方法和应用 | |
CN108078980A (zh) | N,n′-二(7-羟基香豆素-8-基次甲基)肼在制备流感病毒抑制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING OGPHARMA CO., LTD. Free format text: FORMER OWNER: NANJING ZHONGRUI PHARMACEUTICAL CO., LTD. Effective date: 20120702 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210004 NANJING, JIANGSU PROVINCE TO: 210036 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120702 Address after: 210036, Jiangsu, Nanjing, Hanzhoung gate 301, Nanjing international service outsourcing building, block A, on the third floor Patentee after: Nanjing Sino Europe medical science and Technology Service Co., Ltd. Address before: 210004 Jiangsu city of Nanjing province Xinjiekou Tongyu Tangzi Street No. 41 building 10 floor Patentee before: Nanjing Zhongrui Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20140918 |
|
EXPY | Termination of patent right or utility model |